Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)
Pfizer
3,501 participants
Dec 19, 2025
INTERVENTIONAL
Conditions
Summary
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Once-weekly MET097 administered via subcutaneous injection
Once-weekly placebo administered via subcutaneous injection
Locations(171)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07311850